Details of the Drug

General Information of Drug (ID: DMPHZQE)

Drug Name

Chlorpropamide

Synonyms

Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Non-insulin dependent diabetes	5A11	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

276.74

Logarithm of the Partition Coefficient (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: 95% of drug becomes completely available to its intended biological destination(s) [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.045 mL/min/kg [3]
Elimination: 20% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 36 hours [3]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.16814 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.03% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.19 L/kg [3]
Water Solubility: The ability of drug to dissolve in water is measured as 2.2 mg/mL [4]

Chemical Identifiers

Formula: C10H13ClN2O3S
IUPAC Name: 1-(4-chlorophenyl)sulfonyl-3-propylurea
Canonical SMILES: CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
InChI: InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
InChIKey: RKWGIWYCVPQPMF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2727
ChEBI ID: CHEBI:3650
CAS Number: 94-20-2
DrugBank ID: DB00672
TTD ID: D00BCP
VARIDT ID: DR00478
INTEDE ID: DR0311
ACDINA ID: D00125

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inward rectifier potassium channel Kir1.2 (KCNJ10)	TTG140O	KCJ10_HUMAN	Blocker	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[8]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Gene/Protein Processing	[9]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Gene/Protein Processing	[10]
Vasopressin-neurophysin 2-copeptin (AVP)	OTAVZ76K	NEU2_HUMAN	Protein Interaction/Cellular Processes	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlorpropamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Chlorpropamide due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[12]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[13]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Chlorpropamide caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[14]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Chlorpropamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Oxymetholone.	Aplastic anaemia [3A70]	[16]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[16]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Chlorpropamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[18]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[18]
Phenylbutazone	DMAYL0T	Moderate	Decreased metabolism of Chlorpropamide caused by Phenylbutazone.	Chronic pain [MG30]	[19]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Ketoprofen.	Chronic pain [MG30]	[18]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Chlorpropamide and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[20]
Ardeparin	DMYRX8B	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Ardeparin.	Coronary thrombosis [BA43]	[18]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Chlorpropamide caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[21]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Chlorpropamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Chlorpropamide caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[23]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Sertraline.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Vilazodone.	Depression [6A70-6A7Z]	[18]
Paroxetine	DM5PVQE	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Paroxetine.	Depression [6A70-6A7Z]	[18]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Selegiline.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Vortioxetine.	Depression [6A70-6A7Z]	[18]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Isocarboxazid.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Escitalopram.	Depression [6A70-6A7Z]	[18]
Tranylcypromine	DMGB5RE	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Tranylcypromine.	Depression [6A70-6A7Z]	[16]
Phenelzine	DMHIDUE	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Phenelzine.	Depression [6A70-6A7Z]	[18]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[13]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and PMID28870136-Compound-49.	Discovery agent [N.A.]	[18]
Oxcarbazepine	DM5PU6O	Moderate	Decreased metabolism of Chlorpropamide caused by Oxcarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Chlorpropamide caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Mefenamic acid.	Female pelvic pain [GA34]	[18]
Miconazole	DMPMYE8	Major	Decreased metabolism of Chlorpropamide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[18]
Sulfinpyrazone	DMEV954	Moderate	Decreased renal excretion of Chlorpropamide caused by Sulfinpyrazone.	Gout [FA25]	[19]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Chlorpropamide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Chlorpropamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Chlorpropamide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[18]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[18]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Captopril.	Hypertension [BA00-BA04]	[18]
Methyldopa	DM5I621	Minor	Decreased metabolism of Chlorpropamide caused by Methyldopa.	Hypertension [BA00-BA04]	[28]
Perindopril	DMOPZDT	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Perindopril.	Hypertension [BA00-BA04]	[18]
Quinapril	DMR8H31	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Quinapril.	Hypertension [BA00-BA04]	[18]
Lisinopril	DMUOK4C	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Lisinopril.	Hypertension [BA00-BA04]	[18]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[13]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[18]
Balsalazide	DM7I1T9	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Balsalazide.	Indeterminate colitis [DD72]	[18]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[16]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorpropamide and Porfimer Sodium.	Lung cancer [2C25]	[29]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Chlorpropamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[24]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulphadoxine.	Malaria [1F40-1F45]	[16]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Chlorpropamide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[18]
Naproxen	DMZ5RGV	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Naproxen.	Osteoarthritis [FA00-FA05]	[18]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Chlorpropamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[30]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Aspirin.	Pain [MG30-MG3Z]	[16]
Etodolac	DM6WJO9	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Etodolac.	Pain [MG30-MG3Z]	[18]
Diflunisal	DM7EN8I	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Diflunisal.	Pain [MG30-MG3Z]	[18]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Ibuprofen.	Pain [MG30-MG3Z]	[18]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Safinamide.	Parkinsonism [8A00]	[18]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Rasagiline.	Parkinsonism [8A00]	[18]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Chlorpropamide due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[31]
Esomeprazole	DM7BN0X	Minor	Decreased metabolism of Chlorpropamide caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[32]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Chlorpropamide due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[31]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[16]
Bromfenac	DMKB79O	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Bromfenac.	Postoperative inflammation [1A00-CA43]	[16]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Chlorpropamide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[33]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Chlorpropamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[34]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Salsalate.	Rheumatoid arthritis [FA20]	[18]
Meloxicam	DM2AR7L	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Meloxicam.	Rheumatoid arthritis [FA20]	[18]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Oxaprozin.	Rheumatoid arthritis [FA20]	[18]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Flurbiprofen.	Rheumatoid arthritis [FA20]	[18]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulfasalazine.	Rheumatoid arthritis [FA20]	[18]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Chlorpropamide caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[35]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[16]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[18]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[18]
Warfarin	DMJYCVW	Moderate	Increased plasma concentration of Chlorpropamide and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[20]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[18]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Chlorpropamide and Olsalazine.	Ulcerative colitis [DD71]	[18]
-----------


⏷ Show the Full List of 79 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aminoethanoic acid	E00025	750	Buffering agent; Disintegrant; Lyophilization aid
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorpropamide 100 mg tablet	100 mg	Oral Tablet	Oral
Chlorpropamide 250 mg tablet	250 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6801).
2	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	BDDCS applied to over 900 drugs
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
7	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
8	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
9	Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
10	Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
11	Inappropriate secretion of antidiuretic hormone induced by chlorpropamide. Am J Med Sci. 1972 Mar;263(3):137-41. doi: 10.1097/00000441-197203000-00002.
12	Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
13	Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
14	Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
17	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
18	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
19	Mahfouz M, Abdel-Maguid R, El-Dakhakhny M "Potentiation of the hypoglycaemic action of tolbutamide by different drugs." Arzneimittelforschung 20 (1970): 120-2. [PMID: 5467602]
20	Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
21	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
22	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
23	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
24	Cerner Multum, Inc. "Australian Product Information.".
25	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
26	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
27	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
28	Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
29	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
30	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
31	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
32	Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
33	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
34	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
35	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.